Ratios

		vs industry	vs history
P/E(ttm)	136.40	HSP's P/E(ttm) is ranked higher than 74% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 29.76 vs. HSP: 136.40 )	HSP' s 10-Year P/E(ttm) Range Min: 8.48   Max: 136.41 Current: 136.4 8.48 136.41
P/B	1.94	HSP's P/B is ranked higher than 70% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.00 vs. HSP: 1.94 )	HSP' s 10-Year P/B Range Min: 1.52   Max: 5.9 Current: 1.94 1.52 5.9
P/S	1.45	HSP's P/S is ranked higher than 70% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.32 vs. HSP: 1.45 )	HSP' s 10-Year P/S Range Min: 0.99   Max: 2.89 Current: 1.45 0.99 2.89
PFCF	33.40	HSP's PFCF is ranked higher than 66% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 25.89 vs. HSP: 33.40 )	HSP' s 10-Year PFCF Range Min: 8.32   Max: 115.56 Current: 33.4 8.32 115.56
EV-to-EBIT	117.86	HSP's EV-to-EBIT is ranked lower than 59% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 21.70 vs. HSP: 117.86 )	HSP' s 10-Year EV-to-EBIT Range Min: 10   Max: 127.9 Current: 117.86 10 127.9
Shiller P/E	26.54	HSP's Shiller P/E is ranked higher than 85% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 30.12 vs. HSP: 26.54 )	HSP' s 10-Year Shiller P/E Range Min: 12.55   Max: 33.08 Current: 26.54 12.55 33.08

Valuation & Return

		vs industry	vs history
Price/Net Current Asset Value	5.7	HSP's Price/Net Current Asset Value is ranked higher than 60% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 10.20 vs. HSP: 5.7 )	HSP' s 10-Year Price/Net Current Asset Value Range Min: 4.8   Max: 14 Current: 5.7 4.8 14
Price/Tangible Book	3.5	HSP's Price/Tangible Book is ranked higher than 72% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.40 vs. HSP: 3.5 )	HSP' s 10-Year Price/Tangible Book Range Min: 3.1   Max: 21.1 Current: 3.5 3.1 21.1
Price/DCF (Projected)	1.1	HSP's Price/DCF (Projected) is ranked higher than 76% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.60 vs. HSP: 1.1 )	HSP' s 10-Year Price/DCF (Projected) Range Min: 0.9   Max: 1.4 Current: 1.1 0.9 1.4
Price/Median PS Value	0.7	HSP's Price/Median PS Value is ranked higher than 72% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.70 vs. HSP: 0.7 )	HSP' s 10-Year Price/Median PS Value Range Min: 0.6   Max: 1.3 Current: 0.7 0.6 1.3
Price/Graham Number	4.6	HSP's Price/Graham Number is ranked higher than 99% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.30 vs. HSP: 4.6 )	HSP' s 10-Year Price/Graham Number Range Min: 2.1   Max: 4 Current: 4.6 2.1 4
Earnings Yield (Greenblatt)	0.80	HSP's Earnings Yield (Greenblatt) is ranked higher than 64% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.90 vs. HSP: 0.80 )	HSP' s 10-Year Earnings Yield (Greenblatt) Range Min: 0.8   Max: 10 Current: 0.8 0.8 10
Forward Rate of Return (Yacktman)	4.91	HSP's Forward Rate of Return (Yacktman) is ranked higher than 71% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 9.82 vs. HSP: 4.91 )	HSP' s 10-Year Forward Rate of Return (Yacktman) Range Min: 5.9   Max: 20.4 Current: 4.91 5.9 20.4

Business Description

Hospira, Inc. was incorporated in Delaware on September 16, 2003, as a wholly owned subsidiary of Abbott Laboratories. On April 30, 2004, it began operating as an independent company. The Company is a global provider of injectable drugs and infusion technologies. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa; and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the APAC segment includes Asia, Japan, Australia and New Zealand. The Company's specialty injectable pharmaceutical products category mainly consists of generic injectable pharmaceuticals. These products provide customers with a lower-cost alternative to branded products, when the patent protection has expired, when patents have been declared invalid, or when the products do not infringe the patents of others. These drugs' therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other areas. The Company's other pharmaceuticals mainly consist of large volume I.V. solutions, nutritionals and contract manufacturing services. The Company offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for the washing and cleansing of wounds or surgical sites. It also offers infusion therapy solutions in its VisIV(TM) next-generation non-PVC, non-DEHP I.V. container, an I.V. bag with advanced safety and environmentally friendly features. Hospira's contract manufacturing services are offered through its One2One(SM) services group, which provides formulation development, filling and finishing of injectable and oral drugs worldwide. The Company's medication management products include electronic drug delivery pumps, safety software and disposable administration sets dedicated to Hospira pumps. These sets are used to deliver I.V. fluids and medications. Medication management includes TheraDoc, Inc. products, which are module-based clinical surveillance systems that provide patient safety surveillance and clinical decision support. Medication management also includes gravity administration sets and other device products, including needlestick safety products and programs to support Hospira's customers' needlestick prevention initiatives. The Company's main customers in the Americas segment include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its main customers in the EMEA and APAC segments are hospitals and wholesalers that Hospira serves through its own sales
Company Website
SEC Reports

Industry:	Drug Manufacturers - Specialty & Generic
Compare:	TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:	HOS.Germany

» More Articles for HSP

Headlines

Articles On GuruFocus.com

Brian Rogers of T Rowe Price Buys 4 New Stocks, Including Apple in Q1 Apr 17 2013

Investing in Money: Ariel Fund & Ariel Appreciation Fund Q3 Commentary Nov 19 2012

Larry Robbins Grows in Tenet Healthcare Shares Oct 24 2012

Weekly Guru Bargains Highlights: SOHU, NFG, CHK, HSP, PT Feb 10 2012

Edward Owens’ Vanguard Health Care Fund Biggest Buys in Fourth Quarter Jan 30 2012

Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" Jan 11 2012

Meridian Funds Buys AAP, DENN, SWY, MDP, SBAC, FDO, GMT, HURN Oct 31 2011

Meridian Fund Annual Report, Commentary on ARCO, NSC, GMT, ICON, COST, Others Sep 07 2011

Hospira Inc. (HSP) SVP and CFO Thomas E Werner sells 15,181 Shares Mar 10 2011

Weekly Top Insider Sells: QCOM, GPS, ORCL, HSP and MSFT Dec 26 2010

Personalized Checklist